Latest News

Valneva inks $59m JE vaccine supply contract

Valneva headquarters. © Valneva SE


by tg

French vaccine specialist Valneva SE has inked a supply contract with the US Department of Defense for IXIARO its Japanese encephalitis (JE). 

Under the agreement, Valneva will supply its FDA-approved preventive vaccine for Japanese encephalitis (JE) from 2019 to 2020. There is a minimum order quantity of doses worth $59m, which can be increased to $70m.

"The U.S. military has been using IXIARO since 2010 and we are excited to further support the expansion of its use and help protect military personnel and their families from Japanese encephalitis," commented Franck Grimaud, Chief Business Officer of Valneva. 

In October, the FDA approved an accelerated vaccination schedule for the active immunisation, that was developed under an collaboration agreement with the Walter Reed Army Institute of Research of two doses administered seven days apart (before 28 days) for adult travelers aged 18-65 years. 

JE is an infectious disease with an estimated 70,000 cases annually in Asia, 30% of which are deadly. Half of survivors have permanent brain damage. The disease is endemic in Southeast Asia, India and China. 

Nutrition influences the course of MS

In Cell the team headed by Aiden Haghikia from University Bochum demonstrated that the administration of propionic acid (PA) in addition to MS...

MercachemSyncom, Bionetix, and ProQinase ink AML contract

"We are excited to start this new project with MercachemSyncom and ProQinase," said Dr. DooYoung Jung, CEO of the Korean cancer drug...

Vitamin C may boost checkpoint inhibitor efficacy

Results obtained from mice models suggest that the vitamin should be tested as a supporting treatment for cancer patients receiving immunotherapies....

Novadiscovery takes off with €5 Series A financing

French in silico clinical trial specialist Novadiscovery said it will use the €5m tranche of a €7m Series A funding round with Debiopharm Innovation...

Illumina embraces Roche

Just in time for the start of the JP Morgan conference, Roche and Illumina, the competitors in the emerging market of NGS-based cancer patient...

Merry Christmas and a Happy New Year

North Sea Therapeutics raises US$40m in Series B

Besides the completion of the ongoing Phase 2b ICONA study on icosabutate in safety and efficacy in NASH (Non-alcoholic Steatohepatitis), North Sea...